On Monday, Johnson & Johnson (NYSE:JNJ) announced a sweeping agreement to settle its outstanding talc-related lawsuits.
The proposed resolution, coordinated with lead plaintiff firms in federal Multi-District Litigation (MDL) and state courts, requires a 95% participation rate among remaining claimants to move forward.
Lack Of Scientific Merit Leads To Favorable Ruling
The settlement arrives on the heels of a favorable court decision highlighting the plaintiffs’ inability to demonstrate specific causation connecting the company’s talc products to individual cases of ovarian cancer.
The company has successfully defended itself in the vast majority of ovarian trials to date.
